Prolonged wild-type p53 protein accumulation and cisplatin resistance

被引:30
作者
Yazlovitskaya, EM [1 ]
DeHaan, RD [1 ]
Persons, DL [1 ]
机构
[1] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA
关键词
ovarian carcinoma; cisplatin sensitivity; p53; p21(WAF-1); Mdm2;
D O I
10.1006/bbrc.2001.4849
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The major limitation for the chemotherapeutic use of DNA-damaging agent cisplatin is the development of resistance in initially responsive tumors. One of the main pathways regulating cell survival following DNA damage is the p53 pathway. In this study we compared the cisplatin-induced response of p53 protein and its downstream targets p21(WAF-1) and Mdm2 in the cisplatin-sensitive ovarian carcinoma cell line A2780 and its cisplatin-resistant derivative CP70. A higher dose of cisplatin and a longer exposure time was required to achieve the same level of p53, p21(WAF-1) and Mdma protein accumulation in the cisplatin-resistant CP70 cells versus cisplatin-sensitive A2780 cells. A significant difference between the two cell lines was observed in cisplatin-induced stabilization of p53 protein. The p53 half-life increased 31-fold in CP70 cells compared to only g-fold in A2780 cells. In contrast, there was no difference in p21(WAF-1) half-life between the two cell lines. These results demonstrate that in A2780 and CP70 cells resistance to cisplatin correlates with prolonged p53 protein stabilization and accumulation. (C) 2001 Academic Press.
引用
收藏
页码:732 / 737
页数:6
相关论文
共 30 条
[1]   Maintenance of genomic integrity by p53:: complementary roles for activated and non-activated p53 [J].
Albrechtsen, N ;
Dornreiter, I ;
Grosse, F ;
Kim, E ;
Wiesmüller, L ;
Deppert, W .
ONCOGENE, 1999, 18 (53) :7706-7717
[2]   Regulation of p53 stability [J].
Ashcroft, M ;
Vousden, KH .
ONCOGENE, 1999, 18 (53) :7637-7643
[3]   Loss of function and p53 protein stabilization [J].
Blagosklonny, MV .
ONCOGENE, 1997, 15 (16) :1889-1893
[4]   INCREASED ACCUMULATION OF P53 PROTEIN IN CISPLATIN-RESISTANT OVARIAN CELL-LINES [J].
BROWN, R ;
CLUGSTON, C ;
BURNS, P ;
EDLIN, A ;
VASEY, P ;
VOJTESEK, B ;
KAYE, SB .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (04) :678-684
[5]   Redundant down-regulation pathways for p53 [J].
Cinelli, M ;
Magnelli, L ;
Chiarugi, V .
PHARMACOLOGICAL RESEARCH, 1998, 37 (02) :83-85
[6]  
Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.0.CO
[7]  
2-D
[8]   DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status [J].
DeFeudis, P ;
Debernardis, D ;
Beccaglia, P ;
Valenti, M ;
Sire, EG ;
Arzani, D ;
Stanzione, S ;
Parodi, S ;
DIncalci, M ;
Russo, P ;
Broggini, M .
BRITISH JOURNAL OF CANCER, 1997, 76 (04) :474-479
[9]  
Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245
[10]   SEPARATION AND CHARACTERIZATION OF PRODUCTS RESULTING FROM THE REACTION OF CIS-DIAMMINEDICHLOROPLATINUM(II) WITH DEOXYRIBONUCLEOSIDES [J].
EASTMAN, A .
BIOCHEMISTRY, 1982, 21 (26) :6732-6736